Acute Kidney Injury in Premature Infants
Acute Kidney Injury
|Study Design:||Time Perspective: Prospective|
|Official Title:||Acute Kidney Injury in Premature Infants|
- Characterize the incidence and risk factors in critically ill premature infants [ Time Frame: 2 years ]
- Compare hospital of premature infants outcomes with and without AKI. Test ability of known noninvasive urinary biomarkers' ability to detect AKI in premature infants [ Time Frame: 2 years ]
|Study Start Date:||December 2007|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
Advancements in the field of peri-natal medicine has improved the survival of critically ill neonates but yet many still do not survive, and many more are left with long-term damage to vital organ systems. Very little data is available on the impact that acute kidney injury (AKI) has on survival in premature infants, but adult and pediatric studies that show that even mild AKI independently impacts survival after correcting for severity of illness. The role that AKI impacts survival in premature infants is likely to be greater than adults as this acute injury occurs in context of impaired and ongoing kidney development..
Our ability to improve outcomes in children and adults with AKI has been hampered by the inability to recognize AKI early in the disease process. Thus, the work on early non-invasive biomarkers of renal injury has brought great optimism to the field of AKI. Serum and urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), urinary interleukin 18 (IL-18) others are markedly elevated several hours after AKI as opposed to serum creatinine which takes days to rise after the inciting event. Early non-invasive biomarkers of AKI have not been tested in premature infants.
Inclusion criteria - infants (birthweight 500-1500g) be asked to participate in the study. • Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded
Please refer to this study by its ClinicalTrials.gov identifier: NCT00573079
|United States, Alabama|
|Birmingham, Alabama, United States, 35233|
|Principal Investigator:||David Askenazi, MD||University of Alabama at Birmingham|